Shares of Humacyte, Inc. (HUMA) surged over 11% in trading on Thursday, October 18, fueled by a wave of positive analyst ratings and reports from several Wall Street firms. The biotech company's stock price soared amidst growing investor optimism and confidence in its prospects.
Leading the bullish sentiment was TD Cowen analyst Josh Jennings, who reiterated a "Buy" rating on HUMA and set a price target of $10.00. Jennings' favorable outlook highlighted the potential of Humacyte's regenerative medicine technology and its potential to drive future growth.
Piper Sandler analyst Allison Bratzel also weighed in, maintaining a "Hold" rating on the stock but raising the firm's price target to $6.00. While more cautious, Bratzel's revised target suggests potential upside for HUMA based on the company's ongoing development efforts.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。